ロード中...
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
AIMS: Hypoglycaemia, in patients with Type 2 diabetes (T2D) is associated with an increased risk for cardiovascular (CV) events. In EMPA-REG OUTCOME, the sodium-glucose co-transporter-2 inhibitor empagliflozin reduced the risk of CV death by 38% and heart failure hospitalization (HHF) by 35%, while...
保存先:
| 出版年: | Eur Heart J |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6945517/ https://ncbi.nlm.nih.gov/pubmed/31504427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehz621 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|